BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $340.30.

Several equities research analysts recently weighed in on ONC shares. Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 18th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd. Guggenheim raised their target price on BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Royal Bank Of Canada raised their target price on BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a report on Thursday, August 7th. Finally, JPMorgan Chase & Co. raised their target price on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a report on Wednesday, October 8th.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $316.15 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72. The stock has a fifty day moving average price of $323.50 and a 200 day moving average price of $277.84. BeOne Medicines has a 1-year low of $170.99 and a 1-year high of $355.30. The company has a market cap of $34.65 billion, a PE ratio of -182.74 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.24 billion. Sell-side analysts forecast that BeOne Medicines will post -5.82 EPS for the current year.

Insiders Place Their Bets

In other news, insider Lai Wang sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total value of $1,750,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $337.00, for a total value of $898,105.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 164,184 shares of company stock valued at $51,534,146. Company insiders own 6.62% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Anchor Investment Management LLC purchased a new position in shares of BeOne Medicines in the second quarter valued at $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in BeOne Medicines during the 2nd quarter worth about $28,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines during the 2nd quarter worth about $35,000. Farther Finance Advisors LLC purchased a new stake in BeOne Medicines during the 2nd quarter worth about $39,000. Finally, Signaturefd LLC purchased a new stake in BeOne Medicines during the 2nd quarter worth about $49,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.